Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors

Antibodies that mediate non-neutralizing functions play an important role in the immune response to Ebola virus (EBOV) and are thought to impact disease outcome. EBOV has also been associated with long term sequelae in survivors, however, the extent to which antibodies that mediate non-neutralizing functions are associated with the development of these sequelae is unknown. Here, the presence of antibodies mediating different effector functions and how they relate to long-term sequelae two years after the 2007 Bundibugyo Ebola virus (BDBV) outbreak was investigated. The majority of survivors demonstrated robust antibody effector functional activity and demonstrated persistent polyfunctional antibody profiles to the EBOV glycoprotein (GP) two years after infection. These functions were strongly associated with the levels of GP-specific IgG1. The odds of developing hearing loss, one of the more common sequelae to BDBV was reduced when antibodies mediating antibody dependent cellular phagocytosis (ADCP), antibody dependent complement deposition (ADCD), or activating NK cells (ADNKA) were observed. In addition, hearing loss was associated with increased levels of several pro-inflammatory cytokines and levels of these pro-inflammatory cytokines were associated with lower ADCP. These results are indicating that a skewed antibody profile and persistent inflammation may contribute to long term outcome in survivors of BDBV infection

[1]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[2]  David A. Drew,et al.  Attributes and predictors of long COVID , 2021, Nature Medicine.

[3]  P. Horby,et al.  Ebola virus antibody decay–stimulation in a high proportion of survivors , 2021, Nature.

[4]  Y. Kawaoka,et al.  A Fc-Engineering Approach to Define Functional Humoral Correlates of Immunity Against Ebola Virus , 2020, SSRN Electronic Journal.

[5]  P. Maes,et al.  Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study , 2020, The Lancet Infectious Diseases.

[6]  Anthony K. P. Jones,et al.  Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. , 2020, Journal of rehabilitation medicine.

[7]  Donald S. Grant,et al.  Ebola-Specific CD8+ and CD4+ T Cell Responses in Sierra Leonean Ebola Virus Survivors with and without Post Viral Sequelae. , 2020, The Journal of infectious diseases.

[8]  C. Levy-marchal,et al.  Long-lasting severe immune dysfunction in Ebola virus disease survivors , 2019, Nature Communications.

[9]  G. Firestein,et al.  Chronic Joint Pain 3 Years after Chikungunya Virus Infection Largely Characterized by Relapsing-remitting Symptoms , 2019, The Journal of Rheumatology.

[10]  J. Anaya,et al.  Ebola virus disease: An emerging and re-emerging viral threat. , 2019, Journal of autoimmunity.

[11]  Donald S. Grant,et al.  Long-Term Complications of Ebola Virus Disease: Prevalence and Predictors of Major Symptoms and the Role of Inflammation. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Tokiko Watanabe,et al.  Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study , 2019, PLoS neglected tropical diseases.

[13]  B. Gunn,et al.  Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses , 2019, The Journal of infectious diseases.

[14]  G. Alter,et al.  A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation☆ , 2019, Journal of immunological methods.

[15]  G. Alter,et al.  A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis , 2019, Journal of immunological methods.

[16]  J. Routy,et al.  Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation , 2019, Medicine.

[17]  Rodolphe Thiebaut,et al.  Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  J. Dye,et al.  Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection , 2018, Cell.

[19]  D. Lauffenburger,et al.  A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. , 2018, Cell host & microbe.

[20]  M. Pauly,et al.  Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. , 2018, The Journal of infectious diseases.

[21]  T. Monath,et al.  Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. , 2018, The Lancet. Infectious diseases.

[22]  M. Cranfield,et al.  Suspected Exposure to Filoviruses Among People Contacting Wildlife in Southwestern Uganda. , 2018, The Journal of infectious diseases.

[23]  Y. Sakurai,et al.  Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates , 2018, The Journal of infectious diseases.

[24]  Samantha E. Zak,et al.  Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail , 2018, Viruses.

[25]  J. Shiloach,et al.  Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo , 2018, The Journal of infectious diseases.

[26]  B. Nicholson,et al.  Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection , 2017, The Journal of infectious diseases.

[27]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[28]  M. Wang,et al.  Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection , 2017, Scientific Reports.

[29]  Sarah L. Keasey,et al.  Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses , 2016, Clinical and Vaccine Immunology.

[30]  J. Mascola,et al.  Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody , 2016, Science.

[31]  D. Burton,et al.  Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak , 2016, Science.

[32]  G. Olinger,et al.  Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. , 2015, Lancet. Infectious Diseases (Print).

[33]  Jay B. Varkey,et al.  Human Ebola virus infection results in substantial immune activation , 2015, Proceedings of the National Academy of Sciences.

[34]  J. M. Carter,et al.  Multiplexed Microsphere Suspension Array-Based Immunoassays. , 2015, Methods in molecular biology.

[35]  P. Roddy A Call to Action to Enhance Filovirus Disease Outbreak Preparedness and Response , 2014, Viruses.

[36]  K. Porten,et al.  Emerging Filoviral Disease in Uganda: Proposed Explanations and Research Directions , 2014, The American journal of tropical medicine and hygiene.

[37]  C. Bailey-Kellogg,et al.  High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. , 2012, Journal of immunological methods.

[38]  H. Feldmann,et al.  Ebola haemorrhagic fever , 2011, The Lancet.

[39]  D. Irvine,et al.  A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.

[40]  M. Nanyunja,et al.  Ebola Hemorrhagic Fever Associated with Novel Virus Strain, Uganda, 2007–2008 , 2010, Emerging infectious diseases.

[41]  N. Wauquier,et al.  High Prevalence of Both Humoral and Cellular Immunity to Zaire ebolavirus among Rural Populations in Gabon , 2010, PloS one.

[42]  N. Sullivan,et al.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.

[43]  W. Ian Lipkin,et al.  Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda , 2008, PLoS pathogens.

[44]  Pedagógia,et al.  Cross Sectional Study , 2019 .

[45]  M. Lederman,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Nature Medicine.

[46]  J Bertolli,et al.  Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. , 1999, The Journal of infectious diseases.

[47]  P. Rollin,et al.  Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. , 1999, The Journal of infectious diseases.